Business Description
TCM Biotech International Corp
NAICS : 325412
SIC : 2836
ISIN : TW0004169008
Description
TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.21 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 2.79 | |||||
| Interest Coverage | 11.34 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.38 | |||||
| Beneish M-Score | -2.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 7.8 | |||||
| 3-Year EBITDA Growth Rate | -5.8 | |||||
| 3-Year EPS without NRI Growth Rate | -12 | |||||
| 3-Year Book Growth Rate | 20.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.2 | |||||
| 9-Day RSI | 39.92 | |||||
| 14-Day RSI | 41.87 | |||||
| 6-1 Month Momentum % | 5.82 | |||||
| 12-1 Month Momentum % | 1.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.03 | |||||
| Quick Ratio | 5.08 | |||||
| Cash Ratio | 3.74 | |||||
| Days Inventory | 142.82 | |||||
| Days Sales Outstanding | 81.88 | |||||
| Days Payable | 41.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.48 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| 3-Year Dividend Growth Rate | -55 | |||||
| Forward Dividend Yield % | 0.48 | |||||
| 5-Year Yield-on-Cost % | 0.48 | |||||
| 3-Year Average Share Buyback Ratio | -5.4 | |||||
| Shareholder Yield % | 1.55 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.32 | |||||
| Operating Margin % | 3.08 | |||||
| Net Margin % | 2.4 | |||||
| FCF Margin % | 5.58 | |||||
| ROE % | 2.27 | |||||
| ROA % | 1.74 | |||||
| ROIC % | 3.35 | |||||
| 3-Year ROIIC % | -22.78 | |||||
| ROC (Joel Greenblatt) % | 4.59 | |||||
| ROCE % | 2.7 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 173.53 | |||||
| PE Ratio without NRI | 178.79 | |||||
| Shiller PE Ratio | 126.83 | |||||
| PEG Ratio | 297.98 | |||||
| PS Ratio | 4.15 | |||||
| PB Ratio | 3.32 | |||||
| Price-to-Tangible-Book | 3.39 | |||||
| Price-to-Free-Cash-Flow | 75.34 | |||||
| Price-to-Operating-Cash-Flow | 69.57 | |||||
| EV-to-EBIT | 117.19 | |||||
| EV-to-EBITDA | 62.28 | |||||
| EV-to-Revenue | 3.64 | |||||
| EV-to-FCF | 65.85 | |||||
| Price-to-GF-Value | 1.28 | |||||
| Price-to-Projected-FCF | 5.72 | |||||
| Price-to-Median-PS-Value | 1.31 | |||||
| Price-to-Graham-Number | 5.18 | |||||
| Price-to-Net-Current-Asset-Value | 4.95 | |||||
| Price-to-Net-Cash | 9.9 | |||||
| Earnings Yield (Greenblatt) % | 0.85 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 0.63 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers